Zobrazeno 1 - 5
of 5
pro vyhledávání: '"M Moreno Palomino"'
Autor:
Inmaculada Jiménez-Nácher, E Villamañán Bueno, M Moreno Palomino, E Rodriguez Martin, A Arancón Pardo, C Sobrino Jiménez, M. A. González Fernández, C Bilbao Gómez-Martino, F Moreno Ramos, M García-Trevijano, A Herrero Ambrosio
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Currently, several disease modifying drugs are approved for multiple sclerosis (MS). IFNβ-1b, IFNβ-1a, pegIFNβ-1a, glatiramer acetate, teriflunomide and dimethylfumarate are indicated for firstline therapy. Secondline tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2496dc578ec32b0073279c264eea77a6
https://doi.org/10.1136/ejhpharm-2020-eahpconf.210
https://doi.org/10.1136/ejhpharm-2020-eahpconf.210
Autor:
A Ambrosio Herrero, N Blazquez-Ramos, M Moreno Palomino, JA Romero Garrido, C Sobrino Jiménez, C Bilbao Gómez-Martino
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance New recombinant long half-life factors VIII (RLHF) have been added to the therapeutic arsenal with the aim of improving the treatment of patients with severe haemophilia A as prophylaxis. After 2 years of treatment, we want
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00021b314fbe2b74c6491bacebbc2af0
https://doi.org/10.1136/ejhpharm-2020-eahpconf.327
https://doi.org/10.1136/ejhpharm-2020-eahpconf.327
Autor:
J Alvarez Criado, A Herrero Ambrosio, C Jimenez Vicente, C Jimenez Nunez, P Lucena Martinez, P Gabaldon Garnica, T Perez Robles, M Moreno Palomino
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Lysosomal acid lipase deficiency (LALD) is a rare lysosomal disorder characterised by clinical with dyslipidaemia and steatohepatitis. Sebelipase-alfa is a recombinant human LAL, recently approved for clinical use in LALD. Purpose Evaluati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb2ae664b065d1bac8a360e93e70bdcb
https://doi.org/10.1136/ejhpharm-2019-eahpconf.440
https://doi.org/10.1136/ejhpharm-2019-eahpconf.440
Autor:
M Freire-González, P Lucena-Martínez, Pilar Gómez-Salcedo, C Sobrino-Jiménez, M Moreno-Palomino, Alicia Herrero-Ambrosio
Publikováno v:
Drug information and pharmacotherapy.
Background Opioids can have serious risks and side effects. Improving the way opioids are prescribed through clinical practice guidelines can ensure patients have access to safer, more effective pain treatment. Purpose To assess the level of adherenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0baa37885100639e14607419f7e9d99b
https://doi.org/10.1136/ejhpharm-2017-000640.278
https://doi.org/10.1136/ejhpharm-2017-000640.278
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.